Companies › Ablative Solutions
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Cardiovascular, Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dehydrated alcohol (Ethanol: Dehydrated Alcohol Injection, USP) Renal nerve ablation via neurolytic injection | – | Phase 3 | Hypertension; Prostate Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06703437 | Dehydrated alcohol (Ethanol: Dehydrated Alcohol Injection, USP) | Phase 1 | Prostate Cancer | Oncology | Feb 2023 |
| NCT02910414 | Dehydrated alcohol (Ethanol: Dehydrated Alcohol Injection, USP) | Phase 3 | Hypertension | Cardiovascular | Dec 2023 |
No annotated target.
–
Mercator MedSystems Guerbet THPharm Verity Pharmaceuticals SecuraBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.